Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗

Report date: 2026/05/24 20:00:34

Base Information

Drug NameFluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate
Drug Alias Namefluticasone furoate, vilanterol trifenatate and umeclidinium bromide糠酸氟替卡松/芜地溴铵/Vilanterol糠酸氟替卡松/芜地溴铵/Vilanterol TrifenatateUmeclidinium bromide/vilanterol trifenate/fluticasone furoate氟替美维 +[12] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionMuscarinic acetylcholine receptor M1 antagonistsBeta-2 adrenergic receptor agonistsMuscarinic acetylcholine receptor M5 antagonists +[7] 
TargetsBeta-2 adrenergic receptorGlucocorticoid receptorMuscarinic acetylcholine receptor M2 +[7] 
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryUnited States
Original Approved Date2017/09/18
Country/TerritoryCanadaUnited StatesEU +[6] 
CombinationsYes Fluticasone FuroateUmeclidinium BromideVilanterol Trifenatate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Intellectual Property Development LtdRoyalty Pharma PLCGlaxosmithkline Trading Services Ltd +[6] 
Inactive CompaniesGlaxo Group Ltd
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeR03AL08
Related LinksKEGG